ZLAB
Zai Lab Limited
NASDAQ · Healthcare · Biotechnology · CN
$26.23
−2.85%Year over year
Reported trailing growth
- Revenue
- +5.1%
- EBITDA
- +12.5%
- EBIT
- -6.9%
- EPS
- +69.8%
- Free cash flow
- +28.5%
- Operating cash flow
- +23.9%
Forward estimates
Based on analyst estimates
- Revenue
- +2.8%
- EBITDA
- -32.1%
- EPS
- -24.4%
Three-year CAGR
- Revenue
- +28.9%
- EBITDA
- +32.5%
- EBIT
- +20.8%
- Net income
- +31.7%
- EPS
- +38.5%
- Free cash flow
- +40.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026